Oncimmune Holdings PLC (AIM:ONC) said it is increasingly confident it will hit its annual revenue target of £6.9 million, supported by a growing number of high-value contracts and strong demand from major pharmaceutical clients.
Since early September, Oncimmune has added three new agreements worth £340,000, building on a quarter marked by eight new deals totalling £2.14 million.
Two of the latest agreements involve new research areas for an existing top 10 global pharmaceutical client, underscoring Oncimmune’s success in attracting repeat business from leading companies.
The third contract extends work with another top 'big pharma' client, leveraging Oncimmune's recent technological advance in profiling specific autoantibodies, which the company announced in August.
With these agreements, Oncimmune now has visibility on over 40% of its fiscal year revenue goal.
Chief executive Marting Gouldstone told investors: "Following the fundraise, and successful debt recapitalisation of the business announced on October 18, I am pleased to see that our relentless focus on the commercial side of the business continues to bear fruit.
"These new wins with existing Top 10 Pharma customers keep us on track to be a profitable business in the financial year 2025."